Basic Addyi Information

• INN (International Nonproprietary Name): Flibanserin
• Brand Names Available in Australia: Addyi
• ATC Code: G02CX02
• Forms & Dosages: Tablet, 100 mg
• Manufacturers in Australia: Sprout Pharmaceuticals
• Registration Status in Australia: Prescription only
• OTC / Rx Classification: Prescription only

Everyday Use & Best Practices

The typical dosing recommendation for Addyi is at bedtime. This aligns well with the standard Australian evening routine, allowing users to incorporate it comfortably into their day. Taking the medication at night can help mitigate potential side effects like dizziness or drowsiness, making it a practical choice for those balancing busy lives.

Morning Vs Evening Dosing (Australian Daily Routines)

Taking Addyi before bedtime fits seamlessly into the evening rituals most Australians have, where winding down and preparing for sleep is common. This timing also minimises interference with daily activities, particularly for those with demanding work or family commitments.

Taking With Or Without Meals

When it comes to meals, Addyi should generally be taken on an empty stomach to maximise its effectiveness. If daily routines vary significantly, incorporating Addyi into a consistent mealtime may still work, as long as the time remains consistent each day. Consider setting routines for when to take the medication to ensure it fits effortlessly into your lifestyle.

Safety Priorities

While Addyi provides benefits for many, certain individuals should avoid it. The Therapeutic Goods Administration (TGA) has outlined specific contraindications, which include those with severe hepatic impairment and those using moderate or strong CYP3A4 inhibitors. Ensuring safety is paramount; thus, a thorough medical consultation prior to starting Addyi is essential.

Who Should Avoid It (TGA Safety Notices)

Patients with known hypersensitivity to flibanserin or its excipients should not take Addyi. Its interaction with other medications can pose serious risks. Moreover, individuals who have a history of severe hypotension or have used alcohol while on this medication should exercise caution, as these factors can heighten the risk of adverse effects.

Activities To Limit (Driving, Machinery, Workplace Safety)

Using Addyi may cause dizziness or sleepiness, which necessitates caution, especially when driving or operating machinery. As per Australian regulations, the workplace must promote safety regarding medication use, urging employees to disclose any medications that could impact their ability to perform tasks safely. It's wise to evaluate how Addyi affects personal functionality before engaging in such activities.

Dosage & Adjustments

According to the Pharmaceutical Benefits Scheme (PBS), the recommended dosage for Addyi is 100 mg once daily at bedtime. Following this regimen ensures the effects of flibanserin are optimised, which can be critical for improving the symptoms of hypoactive sexual desire disorder (HSDD).

General Regimen (PBS-Listed Guidelines)

It’s imperative that users adhere to the prescribed dosing schedule. Missing doses can affect treatment efficacy, so it’s advisable to maintain a consistent routine each day. If a dose is missed, users should skip it and continue with the next scheduled dose without doubling up.

Special Cases (Elderly, Indigenous Health, Comorbidities)

For particular populations, such as the elderly or those with specific comorbidities, dosage adjustments may be necessary. Cultural considerations are also essential, particularly in Indigenous health contexts, where traditional approaches might influence the acceptance of Addyi.

User Testimonials

A number of Australian women have shared their experiences with Addyi, noting significant improvements in sexual desire and overall wellbeing. The medication appears to have a positive impact on many, fostering a renewed sense of intimacy and connection.

Positive Reports From Australian Patients

Many Australian patients report that since using Addyi, their sexual desire has returned, enhancing their relationships. Positive feedback highlights the medication's role in improving overall satisfaction and well-being, making a noticeable difference in their lives.

Common Challenges (Forums, ProductReview Insights)

On local platforms and forums, discussions reveal common challenges with Addyi, including reports of side effects such as dizziness and concerns about proper dosing. Collectively, users share valuable insights that can aid new patients in navigating their journey with this treatment.

Buying Guide

Pharmacy sources

In Australia, major pharmacy chains where Addyi can potentially be purchased include Chemist Warehouse, Priceline, and TerryWhite Chemmart. While Addyi is accessible through these pharmacies, it is important to note that a prescription is required. Consultation with a healthcare professional is advised to ensure it is appropriate for individual health circumstances.

Price comparison

When considering the cost of Addyi, it's valuable to weigh the PBS subsidy against private purchases. Under the Pharmaceutical Benefits Scheme (PBS), eligible patients can access Addyi at a lower price, which can make a significant difference for many. However, purchasing privately may provide more immediate access, albeit at a higher cost. Factors such as health insurance coverage, the urgency of treatment, and personal budget might influence where a patient chooses to buy Addyi. Consumers are encouraged to carefully evaluate their options based on their individual circumstances.

What’s Inside & How It Works

Ingredients overview

Addyi contains flibanserin as its active ingredient, which plays a pivotal role in managing hypoactive sexual desire disorder (HSDD) in premenopausal women. This medication is formulated as a 100 mg oral tablet, typically found in blister packs. It's crucial for patients to be aware of potential sensitivities to certain excipients in the formulation, as these can impact tolerability.

Mechanism basics explained simply

Flibanserin functions by influencing neurotransmitters in the brain, specifically targeting serotonin, norepinephrine, and dopamine. This mechanism helps to increase sexual desire by restoring the balance of these chemicals, which is vital in treating HSDD. For premenopausal women experiencing diminished libido, this targeted action of flibanserin can provide a much-needed improvement in their sexual health.

Main Indications

Approved uses under TGA

The Therapeutic Goods Administration (TGA) in Australia has approved Addyi specifically for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval highlights its significance as the first oral medication aimed at addressing this often misunderstood condition, enhancing the quality of life for many women.

Off-label uses in Australian clinics

In addition to its approved use, some healthcare providers in Australia may explore off-label applications of Addyi for other conditions related to sexual dysfunction. These unapproved uses might attract practitioners interested in holistic approaches to sexual health, tapping into the unique needs of individual patients. However, discussing the potential benefits and risks of such off-label uses with a qualified professional is essential before proceeding.

Interaction Warnings

Food interactions

Alcohol consumption can pose significant risks when taken with Addyi, potentially leading to adverse effects such as severe hypotension. Given the social habits in Australia, where alcohol is commonly consumed, this could impact compliance and safety. It's vital for patients to exercise responsible alcohol consumption when using Addyi, ensuring they understand the importance of moderation to avoid complications.

Drug conflicts tracked by TGA & PBS

The TGA monitors various drug interactions, noting specific medications that may conflict with flibanserin. Common drugs requiring caution include certain antidepressants and CNS depressants, as they may enhance drowsiness or lead to unpredictable effects. Consulting a pharmacist for a comprehensive medication review is strongly recommended to ensure safe co-administration and to manage any interactions effectively.

Latest Evidence & Insights

Recent studies on Addyi (flibanserin) have emerged from Australia and globally, showcasing its ongoing evaluation from 2022 to 2025. A pivotal international study indicated that a substantial portion of women reported improved sexual desire with Addyi compared to a placebo. In clinical trials, it showed a statistically significant increase in sexually satisfying events when administered daily, particularly among premenopausal women with Hypoactive Sexual Desire Disorder (HSDD).

While enthusiasm for Addyi grows, safety concerns remain. Reports of side effects like dizziness and nausea prompted researchers to delve deeper, resulting in modified clinical guidelines. They suggest cautious prescribing, particularly with regards to concomitant medications and existing health conditions. Importantly, insights revealed that the treatment might take up to eight weeks to manifest its full effects, reshaping patient expectations and clinician discussions. As Australia updates its clinical guidelines, healthcare providers must weigh the pros and cons of Addyi’s efficacy and safety against patient-specific factors.

Alternative Choices

When exploring treatment options for sexual dysfunction in women, Addyi stands alongside alternatives such as bremelanotide (Vyleesi) among others. Here’s a basic breakdown:

• Addyi (flibanserin):
  • Pros: Oral administration, daily use at bedtime, backed by recent studies indicating efficacy in HSDD.
  • Cons: Potential side effects like dizziness, must avoid alcohol, not suitable for severe hepatic impairment.
• Bremelanotide (Vyleesi):
  • Pros: Injectable, fast-acting, does not require daily regimen, more flexibility in use.
  • Cons: Injection-related discomfort, risk of nausea, not suitable if you have uncontrolled high blood pressure.

Deciding between these options should involve a thorough discussion with a healthcare provider, focusing on the patient's health history and lifestyle preferences.

Regulation Snapshot

The Therapeutic Goods Administration (TGA) oversees the approval process for Addyi in Australia. As of 2025, Addyi maintains its prescription-only status, following its approval in 2015. The Public Benefit Scheme (PBS) also dictates that Addyi is subsidised for eligible patients, making it more accessible. However, the PBS framework also ensures that patients meet specific criteria before receiving the subsidy, which can affect ease of access.

This creates a balance between ensuring safe use and maintaining patient access, particularly vital for premenopausal women facing HSDD.

FAQ Section

Here are a few common questions surrounding Addyi based on pharmacy consultations:

• Is Addyi available in Australia? Yes, Addyi (flibanserin) is available in Australia under prescription.
• How does Addyi work? It works by modulating the neurotransmitters associated with sexual desire, aiming to improve libido in premenopausal women.
• Can I take Addyi if I drink alcohol? No, alcohol should be avoided, as it poses a risk of severe hypotension when combined with Addyi.
• Are there any serious side effects? Possible side effects include dizziness and sleepiness; significant adverse effects must be reported to a healthcare provider.

Guidelines for Proper Use

Pharmacists in Australia offer key insights for optimising Addyi's use:

• Dosage: It’s crucial to adhere to the recommended dosage of 100 mg, taken orally once daily at bedtime.
• Patient Assessment: Thorough discussion of the patient's medical history is necessary to assess suitability and potential risks.
• Monitoring: Schedule a follow-up appointment after eight weeks to evaluate effectiveness and side effects.
• Patient Education: Clearly inform patients about the importance of avoiding alcohol and monitoring for possible side effects.

Following these guidelines ensures the safe and effective use of Addyi, enhancing outcomes for patients with HSDD.

Delivery Information